Jco precision oncology.

DOI: 10.1200/PO.19.00124 JCO Precision Oncology - published online August 14, 2019DOI: 10.1200/PO.21.00524 JCO Precision Oncology no. 6 (2022) e2100524. Published online September 14, 2022. PMID: 36103643. Molecular Tumor Board–Assisted Care in an Advanced Cancer Population: Results of a Phase II Clinical Trial Rachel W. Miller, MD 1. x. Rachel W. Miller. Search for articles by this author ...23 Aug 2021 ... JCO Precision Oncology 2018 :2, 1-13 [Full Text · External Web Site Policy ]. Methods. Wiant K, Geisen E, Creel D, Willis G, Freedman A, de Moor ...The analysis focuses on the independent and cumulative impacts of gaps occurring during seven steps of the precision oncology pathway, from diagnosis to treatment. Results: For every 1,000 patients in the study cohort, 497 (49.7%) are lost to precision oncology because of factors associated with getting biomarker test results. Among the 503 of ...Web

DOI: 10.1200/PO.20.00436 JCO Precision Oncology no. 5 (2021) 744-750. Published online May 3, 2021. Published online May 3, 2021. Excellent Response With Alpelisib and Bicalutamide for Advanced Salivary Duct Carcinoma With PIK3CA Mutation and High Androgen Receptor Expression—A Case ReportDOI: 10.1200/PO.20.00516 JCO Precision Oncology no. 5 (2021) 653-663. Published online April 13, 2021. Published online April 13, 2021. MET Exon 14 Skipping Mutations in Non–Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations

Supported by The Cholangiocarcinoma Foundation (to M.Y.), the National Cancer Institute Specialized Program of Research Excellence (SPORE) in Gastrointestinal Cancers (P50 CA062924), the NIH Center Core Grant (P30 CA006973), and the American Society of Clinical Oncology Career Development Award.As such, scientific outlets in general, and JCO Precision Oncology in particular, owe an immense debt of gratitude to our volunteer peer reviewers. JCO PO strives to provide the highest quality peer review, so in recognition of Peer Review Week 2023 and its theme of Peer Review and The Future of Publishing, ...

The definition of a limit in calculus is the value that a function gets close to but never surpasses as the input changes. Limits are one of the most important aspects of calculus, and they are used to determine continuity and the values of...DOI: 10.1200/PO.20.00417 JCO Precision Oncology no. 5 (2021) 450-454. Published online February 26, 2021. PMID: 34994601. NTRK Alterations in Pediatric High-Risk Malignancies Identified Through European Clinical Sequencing Programs Constitute Promising Drug Targets Elke Pfaff, MD. x. Elke Pfaff. Search for articles by this author ...DOI: 10.1200/PO.19.00115 JCO Precision Oncology - published online October 23, 2019 Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor Program Michael J. Pishvaian, MD, PhD 1, 2. x. Michael J. Pishvaian. Search for articles …WebApr 22, 2021 · PURPOSE CATCH (Comprehensive Assessment of clinical feaTures and biomarkers to identify patients with advanced or metastatic breast Cancer for marker driven trials in Humans) is a prospective precision oncology program that uses genomics and transcriptomics to guide therapeutic decisions in the clinical management of metastatic breast cancer. Herein, we report our single-center experience and ... Jul 9, 2021 · PURPOSE We conducted this systematic review to evaluate the clinical outcomes associated with molecular tumor board (MTB) review in patients with cancer. METHODS A systematic search of PubMed was performed to identify studies reporting clinical outcomes in patients with cancer who were reviewed by an MTB. To be included, studies had to report clinical outcomes, including clinical benefit ...

JCO PO is a peer-reviewed, online-only, article-based journal publishing original research, reports, opinions, and reviews that advance the science and practice of precision oncology and define genomics- and other biomarker-driven clinical care of patients with cancer. Innovative and timely scientific and educational content provide a deeper ...Web

A fellow M.D. is a medical doctor who has been given a fellowship, which is a residency that teaches doctors a sub-specialty, such as internal medicine, movement disorders, gynecologic oncology and pediatric hematology, according to the Uni...

PURPOSE Acute lymphoblastic leukemia (ALL) is the most prevalent cause of childhood cancer and requires a long course of therapy consisting of three primary phases with interval intensification blocks. Although these phases are necessary to achieve remission, the primary chemotherapeutic agents have potentially serious toxicities, which may lead to delays or discontinuations of therapy. The ...DOI: 10.1200/PO.19.00333 JCO Precision Oncology no. 4 (2020) 411-425. Published online April 23, 2020. PMID: 35050738. Targeting HER2 Alterations in Non–Small-Cell Lung Cancer: A Comprehensive Review Jing Zhao, MD 1. x. Jing Zhao. Search for articles by this author. and Yang ...WebDOI: 10.1200/PO.17.00084 JCO Precision Oncology - published online October 3, 2017PURPOSE With the recent approval of the KRAS G12C inhibitor sotorasib for patients with advanced KRAS G12C-mutant non–small cell lung cancer (NSCLC), there is a new need to identify factors associated with activity and toxicity among patients treated in routine practice. MATERIALS AND METHODS We conducted a multicenter retrospective study of patients treated with sotorasib outside of ...Apr 26, 2023 · PURPOSE In the two-cohort phase II KEYNOTE-086 study (ClinicalTrials.gov identifier: NCT02447003), first-line and second-line or later pembrolizumab monotherapy demonstrated antitumor activity in metastatic triple-negative breast cancer (mTNBC; N = 254). This exploratory analysis evaluates the association between prespecified molecular biomarkers and clinical outcomes. METHODS Cohort A ... DOI: 10.1200/PO.19.00292 JCO Precision Oncology no. 4 (2020) 244-257. Published online March 27, 2020. PMID: 32923909. Circulating Tumor DNA Predicts the Response and Prognosis in Patients With Early Breast Cancer Receiving Neoadjuvant Chemotherapy Shunying Li, PhD 1, 2. x. Shunying Li. Search for articles by this author ...JCO Precision Oncology, published online May 14, 2018. https://ascopubs.org/doi/full/10.1200/PO.17.00247. Thyroid Cancer. Busaidy NL, Konda B, Wei L, Wirth LJ ...

DOI: 10.1200/PO.20.00436 JCO Precision Oncology no. 5 (2021) 744-750. Published online May 3, 2021. Published online May 3, 2021. Excellent Response With Alpelisib and Bicalutamide for Advanced Salivary Duct Carcinoma With PIK3CA Mutation and High Androgen Receptor Expression—A Case ReportAug 14, 2019 · DOI: 10.1200/PO.19.00124 JCO Precision Oncology - published online August 14, 2019 Most patients are diagnosed with early-stage breast cancer (EBC), which is potentially curable with standard treatments. 3 Although (neo)adjuvant chemotherapies (NAC) reduce the risk of recurrence and death, approximately 30% of patients with EBC will experience recurrence in the first 10 years after surgery. 4 Recent studies have reported that circulating tumor DNA (ctDNA) detection in ...DOI: 10.1200/PO.20.00187 JCO Precision Oncology no. 4 (2020) 1163-1166. Published online September 29, 2020. PMID: 35050775. Targeted Therapy in BRAF p.K601E–Driven NSCLC: Case Report and Literature Review Felix C. Saalfeld, MD 1, 2. x. Felix C. Saalfeld. Search for articles by this author ...Feb 16, 2022 · The actual frequency of NTRK fusions in thyroid cancer is not known, as some targeted exome sequencing can easily miss fusion event involving introns of certain genes. Studies on frequency of NTRK fusions from a single institution and from the TCGA found NTRK fusion in 10 of 451 (2.2%; four NTRK1 and six NTRK3 fusions) and 12 of 498 (2.4%; five ...

DOI: 10.1200/PO.21.00101 JCO Precision Oncology no. 5 (2021) 1166-1177. Published online July 21, 2021. Published online July 21, 2021. Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases

DOI: 10.1200/PO.22.00294 JCO Precision Oncology no. 7 (2023) e2200294. Published online January 12, 2023. PMID: 36634300. Modeling Costs and Life-Years Gained by Population-Wide Next-Generation Sequencing or Single-Gene Testing in Nonsquamous Non–Small-Cell Lung Cancer in the United States ...Purpose With prospective clinical sequencing of tumors emerging as a mainstay in cancer care, an urgent need exists for a clinical support tool that distills the clinical implications associated with specific mutation events into a standardized and easily interpretable format. To this end, we developed OncoKB, an expert-guided precision …Dec 11, 2019 · Although precision oncology is transforming clinical management of patients with cancer, many hospitals face challenges to effectively implement precision oncology. In addition, the cost and time exerted for genomic profiling needs to be balanced with expectations of benefit for each patient. This article summarizes the effort to implement precision oncology in Japan. The most promising ... Aims & Scope of the Journal. JCO Precision Oncology publishes academic articles describing recent essential contributions in the areas of Biological Sciences, General …DOI: 10.1200/PO.22.00148 JCO Precision Oncology no. 6 (2022) e2200148. Published online September 28, 2022. PMID: 36170624. Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease Relapse Frédéric Cailleux, PhD 1. x. Frédéric Cailleux. Search for articles by this author ...Web22 Aug 2023 ... Veracyte Announces that Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict ...PURPOSE Acute lymphoblastic leukemia (ALL) is the most prevalent cause of childhood cancer and requires a long course of therapy consisting of three primary phases with interval intensification blocks. Although these phases are necessary to achieve remission, the primary chemotherapeutic agents have potentially serious toxicities, which may lead to delays or discontinuations of therapy. The ...DOI: 10.1200/PO.21.00011 JCO Precision Oncology no. 5 (2021) 1687-1698. Published online November 3, 2021. Published online November 3, 2021. Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown PrimaryThe liquid biopsy NGS assay demonstrated excellent concordance with tissue profiling in this multicenter, prospective, clinical validation study, with sensitivity and specificity equivalent to Food and Drug Administration-approved single-gene ctDNA assays. The use of plasma-based molecular profiling …

Jan 27, 2022 · This author is an Associate Editor for JCO Precision Oncology. Journal policy recused the author from having any role in the peer review of this manuscript. Stock and Other Ownership Interests: Ciitizen Corporation, Clariifi, Guidance Genomics. Consulting or Advisory Role: Roche, Roche/Genentech. Speakers' Bureau: Genentech

DOI: 10.1200/PO.21.00002 JCO Precision Oncology no. 6 (2022) e2100002. Published online January 6, 2022. PMID: 35005994Web

This is the context motivating the publication by Stetson et al 10 in JCO Precision Oncology. The authors sent aliquots of plasma to four commercial Clinical Laboratory Improvement Amendments–certified laboratories for plasma NGS and compared this to NGS performed on matched tumor and normal tissue at Foundation Medicine. …For this reason, JCO Precision Oncology has organized this special series of tutorial and review articles on statistical methods for precision oncology that will serve as a bridge between the clinical researcher and statistician communities, will help facilitate the application of new methods, and will stimulate the development of more and ...JCO Precision Oncology (JCO PO) is a peer-reviewed, online-only, article-based journal publishing original research, reports, opinions, and reviews that advance the science and …Purpose A long natural history and a predominant osseous pattern of metastatic spread are impediments to the adoption of precision medicine in patients with prostate cancer. To establish the feasibility of clinical genomic profiling in this disease, we performed targeted deep sequencing of tumor and normal DNA from patients with …PURPOSE Earlier detection of cancer recurrence using circulating tumor DNA (ctDNA) to detect molecular residual disease (MRD) has the potential to dramatically affect cancer management. We review evidence supporting the use of ctDNA as a biomarker for detection of MRD and highlight the potential impact that ctDNA testing could have on the conduct of clinical trials. METHODS We searched the ...DOI: 10.1200/PO.17.00084 JCO Precision Oncology - published online October 3, 2017Aug 14, 2019 · DOI: 10.1200/PO.19.00124 JCO Precision Oncology - published online August 14, 2019 Professional English and Academic Editing Support. Submit to JCO PO. View/Change User Info. Institutions and Librarians. Subscribe to this Journal. Journal of Clinical Oncology. JCO Oncology Practice. JCO Global Oncology. JCO Clinical Cancer Informatics.

Precision oncology strategies are an important and growing component of cancer care. There are over 90 US Food and Drug Administration–approved targeted therapies available for use in eligible patients with cancer, 1 and a recent oncology pipeline report showed that approximately 55% of all oncology clinical trials involved the use of biomarkers. 2 Predictive biomarker testing to help ...Purpose With prospective clinical sequencing of tumors emerging as a mainstay in cancer care, an urgent need exists for a clinical support tool that distills the clinical implications associated with specific mutation events into a standardized and easily interpretable format. To this end, we developed OncoKB, an expert-guided precision …PURPOSE To develop and validate a cross-ancestry integrated risk score (caIRS) that combines a cross-ancestry polygenic risk score (caPRS) with a clinical estimator for breast cancer (BC) risk. We hypothesized that the caIRS is a better predictor of BC risk than clinical risk factors across diverse ancestry groups. METHODS We used diverse retrospective cohort data with longitudinal follow-up ...Instagram:https://instagram. where can i buy penny stocks onlineyeild maxmonthly reittrader funding Oct 31, 2022 · PURPOSE To facilitate implementation of precision medicine in clinical management of cancer, the European Society of Medical Oncology proposed in 2018 a new scale to harmonize and standardize the reporting and interpretation of clinically relevant genomics data (ESMO Scale of Actionability of molecular Targets [ESCAT]). This study aims to characterize the clinical impact of matching targetable ... JCO precision oncology Machine Name 31-Gene Expression Profile Testing in Cutaneous Melanoma and Survival Outcomes in a Population-Based Analysis: A SEER Collaboration. tradeweb stockgold trade platform Journal of Clinical Oncology (JCO) is a high-impact, peer-reviewed medical journal that publishes significant clinical oncology research along with editorials, reviews, and other works that relate to the care of patients with cancer.DOI: 10.1200/PO.20.00241 JCO Precision Oncology no. 5 (2021) 93-102. Published online January 11, 2021. PMID: 34994593. Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non–Small-Cell Lung Cancer ... quarters in circulation worth money Standardizing Brain Magnetic Resonance Imaging using Generative Adversarial Networks: A Multisite Study Approach. Kulkarni, Chaitanya; Dinesh, M. S.; Dekker, Andre; More. …DOI: 10.1200/PO.21.00011 JCO Precision Oncology no. 5 (2021) 1687-1698. Published online November 3, 2021. Published online November 3, 2021. Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown Primary